4'-trifluoromethyl-biphenyl-2-carboxylic acid [(2-allyl)-1,2,3,4-tetrahydroisoquinoline-6-yl] amide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-trifluoromethyl-biphenyl-2-carboxylic acid [(2-allyl)-1,2,3,4-tetrahydroisoquinoline-6-yl] amide
• 英文别名: 4'-trifluoromethyl-biphenyl-2-carboxylic acid (2-allyl-1,2,3,4-tetrahydroisoquinolin-6yl)-amide；N-(2-prop-2-enyl-3,4-dihydro-1H-isoquinolin-6-yl)-2-[4-(trifluoromethyl)phenyl]benzamide
• 化学式: C₂₆H₂₃F₃N₂O
• 分子量: 436.477
• InChiKey: DVTNCNBXZJFPAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4'-trifluoromethyl-biphenyl-2-carboxylic acid-[3-(2-hydroxy-ethyl)-4-hydroxymethyl-phenyl]-amide 、 甲基磺酰氯 、 丙烯胺 在 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 以87%的产率得到4'-trifluoromethyl-biphenyl-2-carboxylic acid [(2-allyl)-1,2,3,4-tetrahydroisoquinoline-6-yl] amide
  参考文献：
  名称：

  Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide

  摘要：

  化合物的化学式（I），其中X为CH.sub.2，CO，CS或SO.sub.2；Y从以下选项中选择：直接连接，具有多达20个碳原子的脂肪烃基，该基团可以被羟基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）酰基，（C.sub.1-C.sub.10）酰氧基或（C.sub.6-C.sub.10）芳基单取代，NH和O取代，前提是如果X为CH.sub.2，则Y为直接连接；Z从以下组中选择：（1）H，卤素，氰基，（2）羟基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）烷基硫基，（C.sub.1-C.sub.10）酰基，硫代苯甲酰（C.sub.1-C.sub.10）烷氧羰基，（3）（C.sub.1-C.sub.10）烷基氨基，二（C.sub.1-C.sub.10）烷基氨基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷基氨基，前提是Y不是O或NH，（4）未取代的乙烯基，（C.sub.6-C.sub.10）芳基，（C.sub.3-C.sub.8）环烷基及其融合苯衍生物，（C.sub.7-C.sub.10）多环烷基，（C.sub.4-C.sub.8）环烯基，（C.sub.7-C.sub.10）多环烯基，（5）（C.sub.6-C.sub.10）芳氧基，（C.sub.6-C.sub.10）芳硫基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷氧基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷基硫基，（C.sub.3-C.sub.8）环烷氧基，（C.sub.4-C.sub.8）环烯氧基，（6）从单环基团和融合多环基团中选择的杂环基，其中所述基团包含总共5至14个环原子，其中所述基团包含总共1至4个环杂原子，独立选择自氧，氮和硫，并且所述基团的各个环可以独立饱和，部分不饱和或芳香，前提是如果X为CH.sub.2，则Z为H或从组（4）和（6）中选择，其中，当Z含有一个或多个环时，所述环可以各自独立地携带0至4个取代基，独立选择自卤素，羟基，氰基，硝基，氧代硫代，氨基磺酰基，苯基苯氧基，苯基硫基，卤苯基硫基，苄基，苄氧基，（C.sub.1-C.sub.10）烷基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）烷氧羰基，（C.sub.1-C.sub.10）烷硫基，（C.sub.1-C.sub.10）烷基氨基，（C.sub.1-C.sub.10）烷基氨基羰基，二（C.sub.1-C.sub.10）烷基氨基，二（C.sub.1-C.sub.10）烷基氨基羰基，二（C.sub.1-C.sub.10）烷氧（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.3）全氟烷基，（C.sub.1-C.sub.3）全氟烷氧基，（C.sub.1-C.sub.10）酰基，（C.sub.1-C.sub.10）酰氧基，（C.sub.1-C.sub.10）酰氧（C.sub.1-C.sub.10）烷基和吡咯啉基；及其药学上可接受的盐。

  公开号：

  US05919795A1

文献信息

• Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide
  申请人：Pfizer INc.

  公开号：US05919795A1

  公开（公告）日：1999-07-06

  Compounds of formula (I), ##STR1## wherin X is CH.sub.2, CO, CS or SO.sub.2 ; Y is selected from: a direct link, aliphatic hydrocarbylene radicals having up to 20 carbon atoms, which radical may be mono-substituted by hydroxy, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)acyl, (C.sub.1 -C.sub.10)acyloxy, or (C.sub.6 -C.sub.10)aryl, NH, and O, provided that if X is CH.sub.2,Y is a direct link; Z is selected from the following groups: (1) H, halo, cyano, (2) hydroxy, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)a1kylthio, (C.sub.1 -C.sub.10)acyl, thiophenylcaronyl (C.sub.1 -C.sub.10)alkoxycarbonyl, (3) (C.sub.1 -C.sub.10)aklkyammo, di(C.sub.1 -C.sub.10)alylamino, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkylamino, provided that Y is not O or NH, (4) unsubstituted vinyl, (C.sub.6 -C.sub.10)aryl, (C.sub.3 -C.sub.8)cycloalkyl and fused benz derivatives thereof, (C.sub.7 -C.sub.10)polycycloalkyl, (C.sub.4 -C.sub.8)cycloalkenyl, (C.sub.7 -C.sub.10)polycycloalkenyl, (5) (C.sub.6 -C.sub.10)aryloxy, (C.sub.6 -C.sub.10)aryltio, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkoxy, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkylthio, (C.sub.3 -C.sub.8)cycloalkyloxy, (C.sub.4 -C.sub.8)cycloalkenyloxy, (6) heterocyclyl sclected from the group consisting of monocyclic radicals and fused polycycuic radicals, wherein said radicals contain a total of from 5 to 14 ring atoms, wherein said radicals contain a total of from 1 to 4 ring heteroatoms independently selocted from oxygen, nitrogen, and sulfur, and wherein the individual rings of said radicals may be independendy satated, partally unsaturated, or aromatic, provided that if X is CH.sub.2, Z is H or is selected from groups (4) and (6), wherein, when Z contains one or more rings, said rings may each independently bear 0 to 4 substituents independently selected from halo, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl phenoxy, phenylthio, halophenylthio, benzyl, benzyloxy, (C.sub.1 -C.sub.10)alkyl, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)alkoxycarbonyl, (C.sub.1 -C.sub.10)althyltio, (C.sub.1 -C.sub.10)altylamino, (C.sub.1 -C.sub.10)alkylaminocarbonyl, di(C.sub.1 -C.sub.10)alkylamino, di(C.sub.1 -C.sub.10)alkylaminocarbonyl, di(C.sub.1 -C.sub.10)alkyo(C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.3)perfluoroalkyl, (C.sub.1 -C.sub.3)perfluoroalkoxy, (C.sub.1 -C.sub.10)acyl, (C.sub.1 -C.sub.10)acyloxy, (C.sub.1 -C.sub.10)acyloxy(C.sub.1 -C.sub.10)alkyl, and pyrrolidinyl; and pharmaceutically acceptable salts thereof.

  化合物的化学式（I），其中X为CH.sub.2，CO，CS或SO.sub.2；Y从以下选项中选择：直接连接，具有多达20个碳原子的脂肪烃基，该基团可以被羟基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）酰基，（C.sub.1-C.sub.10）酰氧基或（C.sub.6-C.sub.10）芳基单取代，NH和O取代，前提是如果X为CH.sub.2，则Y为直接连接；Z从以下组中选择：（1）H，卤素，氰基，（2）羟基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）烷基硫基，（C.sub.1-C.sub.10）酰基，硫代苯甲酰（C.sub.1-C.sub.10）烷氧羰基，（3）（C.sub.1-C.sub.10）烷基氨基，二（C.sub.1-C.sub.10）烷基氨基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷基氨基，前提是Y不是O或NH，（4）未取代的乙烯基，（C.sub.6-C.sub.10）芳基，（C.sub.3-C.sub.8）环烷基及其融合苯衍生物，（C.sub.7-C.sub.10）多环烷基，（C.sub.4-C.sub.8）环烯基，（C.sub.7-C.sub.10）多环烯基，（5）（C.sub.6-C.sub.10）芳氧基，（C.sub.6-C.sub.10）芳硫基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷氧基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷基硫基，（C.sub.3-C.sub.8）环烷氧基，（C.sub.4-C.sub.8）环烯氧基，（6）从单环基团和融合多环基团中选择的杂环基，其中所述基团包含总共5至14个环原子，其中所述基团包含总共1至4个环杂原子，独立选择自氧，氮和硫，并且所述基团的各个环可以独立饱和，部分不饱和或芳香，前提是如果X为CH.sub.2，则Z为H或从组（4）和（6）中选择，其中，当Z含有一个或多个环时，所述环可以各自独立地携带0至4个取代基，独立选择自卤素，羟基，氰基，硝基，氧代硫代，氨基磺酰基，苯基苯氧基，苯基硫基，卤苯基硫基，苄基，苄氧基，（C.sub.1-C.sub.10）烷基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）烷氧羰基，（C.sub.1-C.sub.10）烷硫基，（C.sub.1-C.sub.10）烷基氨基，（C.sub.1-C.sub.10）烷基氨基羰基，二（C.sub.1-C.sub.10）烷基氨基，二（C.sub.1-C.sub.10）烷基氨基羰基，二（C.sub.1-C.sub.10）烷氧（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.3）全氟烷基，（C.sub.1-C.sub.3）全氟烷氧基，（C.sub.1-C.sub.10）酰基，（C.sub.1-C.sub.10）酰氧基，（C.sub.1-C.sub.10）酰氧（C.sub.1-C.sub.10）烷基和吡咯啉基；及其药学上可接受的盐。